Solid tumor/s, Metastatic uveal melanoma, Cancer, Cutaneous Melanoma
IDYAIDEAYA BiosciencesCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Darovasertib (IDE196) + crizotinib in Solid tumor/s, Metastatic uveal melanoma, Cancer, Cutaneous Melanoma. The expected timing is based on the latest available company guidance and may change.
IDE196-001 trial. Collab w/ Pfizer. 8/29/25-Present Ph2 Median OS data at SMR in October 25-28, 2025. 11/04/25:- OptimUM-01 Ph2 1L mUM data: 21.1m OS, 7.0m PFS, 34% ORR, 90% DCR, manageable safety. 02/17/26:- OptimUM-01 Phase 2 HLA*A2-positive metastatic uveal melanoma enrollment ~100 patients targeted complete by Q2 2026. 05/05/26:- Completed OptimUM-01 Ph2 HLA*A2-positive mUM enrollment; data from over 85 patients planned H2 2026. 07/17/26:- OptimUM-01 Ph2 results to be presented at ESMO Oct 23-27, 2026. 08/04/26:- OptimUM-01 ESMO update planned October 2026 with ORR, PFS, and OS data.
Verification
Confirm timing and program details against the company announcement or filing.